Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Adult
Aged
Antineoplastic Agents, Immunological
/ adverse effects
Brain
/ drug effects
Central Nervous System Diseases
/ epidemiology
Female
Germany
/ epidemiology
Humans
Immunosuppressive Agents
/ adverse effects
Lymphoproliferative Disorders
/ epidemiology
Male
Middle Aged
Organ Transplantation
/ adverse effects
Registries
Retrospective Studies
Rituximab
/ adverse effects
CNS
EBV
Lymphoma
PTLD
Whole-brain radiotherapy
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
05
03
2021
accepted:
01
05
2021
pubmed:
12
5
2021
medline:
29
7
2021
entrez:
11
5
2021
Statut:
ppublish
Résumé
Post-transplant lymphoproliferative disorders (PTLD) exclusively affecting the central nervous system-primary CNS-PTLD (pCNS-PTLD)-are rare. There is no standard therapy, and previous case series have included heterogeneous treatment approaches. We performed a retrospective, multi-centre analysis of 14 patients with pCNS-PTLD after solid organ transplantation (SOT) treated in the prospective German PTLD registry with reduction of immunosuppression (RI), whole-brain radiotherapy (WBRT), and concurrent systemic rituximab between 2001 and 2018. Twelve of fourteen patients were kidney transplant recipients and median age at diagnosis was 65 years. Thirteen of fourteen cases (93%) were monomorphic PTLD of the diffuse large B-cell lymphoma type, and 12/13 were EBV-associated. The median dose of WBRT administered was 40 Gy with a median fraction of 2 Gy. The median number of administered doses of rituximab (375 mg/m
Identifiants
pubmed: 33973053
doi: 10.1007/s00277-021-04548-2
pii: 10.1007/s00277-021-04548-2
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immunosuppressive Agents
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2043-2050Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Evens AM, Choquet S, Kroll-Desrosiers AR et al (2013) Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant 13:1512–1522. https://doi.org/10.1111/ajt.12211
doi: 10.1111/ajt.12211
pubmed: 23721553
Crane GM, Powell H, Kostadinov R et al (2015) Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget 6:33849–33866. https://doi.org/10.18632/oncotarget.5292
doi: 10.18632/oncotarget.5292
pubmed: 26460822
pmcid: 4741807
Dugan JP, Haverkos BM, Villagomez L et al (2018) Complete and durable responses in primary central nervous system posttransplant lymphoproliferative disorder with zidovudine, ganciclovir, rituximab, and dexamethasone. Clin Cancer Res 24:3273–3281. https://doi.org/10.1158/1078-0432.CCR-17-2685
doi: 10.1158/1078-0432.CCR-17-2685
pubmed: 29632007
pmcid: 6050103
Dharnidharka VR, Webster AC, Martinez OM et al (2016) Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers 2:15088. https://doi.org/10.1038/nrdp.2015.88
doi: 10.1038/nrdp.2015.88
pubmed: 27189056
Trappe R, Oertel S, Leblond V et al (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13:196–206. https://doi.org/10.1016/S1470-2045(11)70300-X
doi: 10.1016/S1470-2045(11)70300-X
pubmed: 22173060
Trappe RU, Dierickx D, Zimmermann H et al (2017) Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial. J Clin Oncol 35:536–543. https://doi.org/10.1200/JCO.2016.69.3564
doi: 10.1200/JCO.2016.69.3564
pubmed: 27992268
Cavaliere R, Petroni G, Lopes MB et al (2010) Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 116:863–870. https://doi.org/10.1002/cncr.24834
doi: 10.1002/cncr.24834
pubmed: 20052713
Fink SEK, Gandhi MK, Nourse JP et al (2014) A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. Am J Transplant 14:2577–2587. https://doi.org/10.1111/ajt.12858
doi: 10.1111/ajt.12858
pubmed: 25130212
Ferreri AJM, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3:e217-227. https://doi.org/10.1016/S2352-3026(16)00036-3
doi: 10.1016/S2352-3026(16)00036-3
pubmed: 27132696
Ferreri AJM, Cwynarski K, Pulczynski E et al (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4:e510–e523. https://doi.org/10.1016/S2352-3026(17)30174-6
doi: 10.1016/S2352-3026(17)30174-6
pubmed: 29054815
Fox CP, Phillips EH, Smith J et al (2019) Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol 184:348–363. https://doi.org/10.1111/bjh.15661
doi: 10.1111/bjh.15661
pubmed: 30467845
Hoang-Xuan K, Bessell E, Bromberg J et al (2015) Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 16:e322-332. https://doi.org/10.1016/S1470-2045(15)00076-5
doi: 10.1016/S1470-2045(15)00076-5
pubmed: 26149884
Zimmermann H, Trappe RU (2013) EBV and posttransplantation lymphoproliferative disease: what to do? Hematology Am Soc Hematol Educ Program 2013:95–102. https://doi.org/10.1182/asheducation-2013.1.95
doi: 10.1182/asheducation-2013.1.95
pubmed: 24319169
Dierickx D, Tousseyn T, Gheysens O (2015) How I treat posttransplant lymphoproliferative disorders. Blood 126:2274–2283. https://doi.org/10.1182/blood-2015-05-615872
doi: 10.1182/blood-2015-05-615872
pubmed: 26384356
Valavoor SH, Ashraf Z, Narwal R, Ratnam S (2013) Conservative management of post-transplant central nervous system lymphoma. Int Urol Nephrol 45:1219–1222. https://doi.org/10.1007/s11255-012-0146-8
doi: 10.1007/s11255-012-0146-8
pubmed: 22476860
Patrick A, Wee A, Hedderman A et al (2011) High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. J Neurooncol 103:739–743. https://doi.org/10.1007/s11060-010-0425-0
doi: 10.1007/s11060-010-0425-0
pubmed: 20872273
Velvet AJJ, Bhutani S, Papachristos S et al (2019) A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature. Oncotarget 10:437–448. https://doi.org/10.18632/oncotarget.26522
doi: 10.18632/oncotarget.26522
pubmed: 30728897
pmcid: 6355190
Bonney DK, Htwe EE, Turner A et al (2012) Sustained response to intrathecal rituximab in EBV associated post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 58:459–461. https://doi.org/10.1002/pbc.23134
doi: 10.1002/pbc.23134
pubmed: 21584931
Czyzewski K, Styczynski J, Krenska A et al (2013) Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Leuk Lymphoma 54:503–506. https://doi.org/10.3109/10428194.2012.718342
doi: 10.3109/10428194.2012.718342
pubmed: 22873830
Swerdlow SH, Webber SA, Chadburn A, Ferry JA (2017) Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoetic and lymphoid tissues, Revised, 4th edn. International Agency for Research on Cancer, Lyon, pp 453–462
Paya CV, Fung JJ, Nalesnik MA et al (1999) Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517–1525
doi: 10.1097/00007890-199911270-00015
Parker A, Bowles K, Bradley JA et al (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 149:693–705. https://doi.org/10.1111/j.1365-2141.2010.08160.x
doi: 10.1111/j.1365-2141.2010.08160.x
pubmed: 20408848
Abrey LE, Batchelor TT, Ferreri AJM et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043. https://doi.org/10.1200/JCO.2005.13.524
doi: 10.1200/JCO.2005.13.524
pubmed: 15955902
Fernández-Ruiz M, López-Medrano F, Varela-Peña P et al (2012) Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection. Am J Transplant 12:2763–2773. https://doi.org/10.1111/j.1600-6143.2012.04192.x
doi: 10.1111/j.1600-6143.2012.04192.x
pubmed: 22823002
Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574. https://doi.org/10.1200/JCO.2006.06.6910
doi: 10.1200/JCO.2006.06.6910
pubmed: 17008697
Herrlinger U, Schäfer N, Fimmers R et al (2017) Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol 143:1815–1821. https://doi.org/10.1007/s00432-017-2423-5
doi: 10.1007/s00432-017-2423-5
pubmed: 28434043